Harvard Bioscience
HBIO
HBIO
100 hedge funds and large institutions have $178M invested in Harvard Bioscience in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
5.38% more ownership
Funds ownership: 71.57% → 76.95% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
100
Holding in Top 10
2
Calls
$164K
Puts
$1K
Top Buyers
| 1 | +$9.44M | |
| 2 | +$2.74M | |
| 3 | +$2.15M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.12M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.48M |
Top Sellers
| 1 | -$5.94M | |
| 2 | -$1.92M | |
| 3 | -$1.9M | |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
-$1.71M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.43M |